Collaborating to Address Global Public Health Needs

Advancing the best science into a transformational medicine is just the first step to helping people lead healthier lives. We are further committed to making a meaningful difference in global public health. Our aspiration is to help more people in more places have access to our medicines and to sustainable, effective healthcare solutions.

Across Janssen we have launched and continue to support comprehensive efforts toward strengthening the health of communities, improving maternal and child health, and preventing the spread of infectious and preventable diseases worldwide through vaccination. The Janssen Global Public Health group unifies our commitment to research, develop and deliver transformational medicines to address the world’s greatest unmet public health needs by:

  • ensuring we have research efforts focused on neglected diseases and medical needs that disproportionally impact public health settings.
  • creating and facilitating access to sustainable and affordable access to our medicines in developing markets.

We work to identify and develop vaccines, diagnostics, medicines and services to address unmet medical needs in areas such as HIV, multi-drug resistant tuberculosis (MDR-TB), intestinal worms, and neglected tropical diseases.

We constantly strive to look at healthcare challenges differently and from all angles, using innovative approaches and exploring new models to make our products as broadly accessible and affordable to people as possible.

We recognize that the challenges of global public health cannot be solved by one company in isolation. We work closely with governments, healthcare organizations and caregivers to create sustainable and innovative solutions. We also collaborate with members of the global healthcare community, to bring new solutions that deliver years of life and quality of life for people around the world.

Ultimately, we strive to reimagine how our business can deliver on the promise of our medicines across the world. We do this because we want to make a meaningful difference in global public health.

Below are some examples of what we are doing today to address global public health needs:

Addressing a global public health crisis

More than 630,000 people worldwide are living with multi-drug resistant tuberculosis (MDR-TB) worldwide. Recently, we introduced a new option to treat this neglected disease. Through public-private partnerships in R&D, differentiated pricing and collaborations around responsible use and distribution, we are working to ensure the product is accessible in countries where it is approved.

Focusing on neglected tropical diseases

We have joined a coordinated action with several other organizations to eliminate or control by the end of the decade, 10 neglected infectious tropical diseases (NTDs). Read more about this important collaboration here.

Innovating new technologies to prevent HIV infections

We are partnering with PATH an international nonprofit organization, to develop a long-acting injectable formulation of one of our HIV medicines as a possible way to prevent HIV infection.

Ensuring sustainable access in the world’s less developed countries

Since 2006, our Global Public Health HIV Medicines Access & Partnerships has been working to ensure that people in resource-limited countries with HIV/AIDS have effective and sustainable access to HIV medicines and know how to use them safely and appropriately for the best possible outcome.

Collaborating to improve access

Recently, we announced a first-of-its-kind donation program to improve access to our HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa. We are working with a number of organizations to fully maximize the impact and reach of this initiative.